Pharmascript Limited - Period Ending 2019-05-31

Pharmascript Limited - Period Ending 2019-05-31


Pharmascript Limited 04781682 false 2018-06-01 2019-05-31 2019-05-31 The principal activity of the company is that of pharmaceutical consultancy, medical and scientific writing and project management Digita Accounts Production Advanced 6.24.8820.0 Software true 04781682 2018-06-01 2019-05-31 04781682 2019-05-31 04781682 bus:OrdinaryShareClass1 2019-05-31 04781682 core:RetainedEarningsAccumulatedLosses 2019-05-31 04781682 core:ShareCapital 2019-05-31 04781682 core:CurrentFinancialInstruments 2019-05-31 04781682 core:CurrentFinancialInstruments core:WithinOneYear 2019-05-31 04781682 core:FurnitureFittingsToolsEquipment 2019-05-31 04781682 bus:SmallEntities 2018-06-01 2019-05-31 04781682 bus:AuditExemptWithAccountantsReport 2018-06-01 2019-05-31 04781682 bus:FullAccounts 2018-06-01 2019-05-31 04781682 bus:SmallCompaniesRegimeForAccounts 2018-06-01 2019-05-31 04781682 bus:RegisteredOffice 2018-06-01 2019-05-31 04781682 bus:Director1 2018-06-01 2019-05-31 04781682 bus:OrdinaryShareClass1 2018-06-01 2019-05-31 04781682 bus:PrivateLimitedCompanyLtd 2018-06-01 2019-05-31 04781682 bus:Agent1 2018-06-01 2019-05-31 04781682 core:FurnitureFittingsToolsEquipment 2018-06-01 2019-05-31 04781682 countries:England 2018-06-01 2019-05-31 04781682 2018-05-31 04781682 core:FurnitureFittingsToolsEquipment 2018-05-31 04781682 2017-06-01 2018-05-31 04781682 2018-05-31 04781682 bus:OrdinaryShareClass1 2018-05-31 04781682 core:RetainedEarningsAccumulatedLosses 2018-05-31 04781682 core:ShareCapital 2018-05-31 04781682 core:CurrentFinancialInstruments 2018-05-31 04781682 core:CurrentFinancialInstruments core:WithinOneYear 2018-05-31 04781682 core:FurnitureFittingsToolsEquipment 2018-05-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 04781682

Pharmascript Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 31 May 2019

 

Pharmascript Limited

Contents

Company Information

1

Accountants' Report

2

Balance Sheet

3

Notes to the Financial Statements

4 to 7

 

Pharmascript Limited

Company Information

Director

Mrs Kathryn Radford

Registered office

338 Musters Road
West Bridgford
Nottingham
NG2 7DF

Accountants

Henson ReesRussell
4 South Bar Street
Banbury
Oxfordshire
OX16 9AA

 

Chartered Accountants' Report to the Director on the Preparation of the Unaudited Statutory Accounts of
Pharmascript Limited
for the Year Ended 31 May 2019

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Pharmascript Limited for the year ended 31 May 2019 as set out on pages 3 to 7 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at
http://www.icaew.com/en/members/regulations-standards-and-guidance/.

This report is made solely to the Board of Directors of Pharmascript Limited, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of Pharmascript Limited and state those matters that we have agreed to state to the Board of Directors of Pharmascript Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Pharmascript Limited and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Pharmascript Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Pharmascript Limited. You consider that Pharmascript Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Pharmascript Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

Henson ReesRussell
4 South Bar Street
Banbury
Oxfordshire
OX16 9AA

25 February 2020

 

Pharmascript Limited

(Registration number: 04781682)
Balance Sheet as at 31 May 2019

Note

2019
£

2018
£

Fixed assets

 

Tangible assets

4

501

667

Current assets

 

Debtors

5

4,140

22,254

Cash at bank and in hand

 

376,927

446,668

 

381,067

468,922

Creditors: Amounts falling due within one year

6

(23,029)

(29,923)

Net current assets

 

358,038

438,999

Net assets

 

358,539

439,666

Capital and reserves

 

Called up share capital

7

100

100

Profit and loss account

358,439

439,566

Total equity

 

358,539

439,666

For the financial year ending 31 May 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised by the director on 25 February 2020
 

.........................................

Mrs Kathryn Radford
Director

 

Pharmascript Limited

Notes to the Financial Statements for the Year Ended 31 May 2019

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
338 Musters Road
West Bridgford
Nottingham
NG2 7DF

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

 

Pharmascript Limited

Notes to the Financial Statements for the Year Ended 31 May 2019

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Fixtures and fittings

33 1/3% straight line and 25% reducing balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 2 (2018 - 2).

 

Pharmascript Limited

Notes to the Financial Statements for the Year Ended 31 May 2019

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 June 2018

7,425

7,425

At 31 May 2019

7,425

7,425

Depreciation

At 1 June 2018

6,758

6,758

Charge for the year

166

166

At 31 May 2019

6,924

6,924

Carrying amount

At 31 May 2019

501

501

At 31 May 2018

667

667

5

Debtors

2019
£

2018
£

Trade debtors

-

18,600

Prepayments

640

650

Other debtors

3,500

3,004

4,140

22,254

6

Creditors

Creditors: amounts falling due within one year

2019
£

2018
£

Due within one year

Taxation and social security

4,247

2,940

Accruals and deferred income

1,957

1,957

Other creditors

16,825

25,026

23,029

29,923

 

Pharmascript Limited

Notes to the Financial Statements for the Year Ended 31 May 2019

7

Share capital

Allotted, called up and fully paid shares

 

2019

2018

 

No.

£

No.

£

Ordinary of £1 each

100

100

100

100